Company intelligence / Profile preview

Taiwan Golden Biotechnology

Taipei, Taiwan

Ownership: Private
Development stage: Other

Overview

Antroquinonol has demonstrated proof of safety and efficacy in Phase 1/2 clinical trials across multiple indications. In acute myeloid leukemia, 80% of patients showed blast counts less than 5%, and 90% did not require blood transfusion. In pancreatic cancer, positive results showed longer survival compared with standard treatment. As of January 2023, 427 patients have completed clinical studies.

Therapeutic areas: CardiovascularNeurologyDermatologyInfectious DiseasesGastroenterologyOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Taiwan Golden Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taiwan Golden Biotechnology.

Explore the full profile